12:43 PM EDT, 10/22/2024 (MT Newswires) -- Bausch + Lomb ( BLCO ) will report third quarter results on October 30. RBC forecasts revenue of US$1.18 billion and adj. EBITDA of US$219 million

Analyst Douglas Miehm says the third quarter will continue to be influenced by FX headwinds (RBCe: ~$5-10M million).

"Operationally, we expect the focus to be on the company's DED Rx drugs (Miebo/Xiidra), new launches, and any potential supply disruptions at its facilities located in Florida due to the recent hurricanes."

Price target raised to US$23 from US$20 to include a sale scenario (after recent media reports indicating that BLCO is working with advisers to test interest from potential buyers) and incorporate the updated multiples of comps.

Maintain Outperform.

Price: 27.80, Change: -0.68, Percent Change: -2.39